Search clinical trials for: PSMA positive metastatic prostate cancer

Total 95949 results

Fusion Pharmaceuticals Inc.

Recruiting

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (AlphaBreak)

Metastatic Castration-resistant Prostate Cancer

United States
Huashan Hospital

Recruiting

A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled ZT-111 in Patients With Metastatic Prostate Cancer

Prostate Specific Membrane Antigen Positive Metastatic Prostate Cancer

China
Novartis Pharmaceuticals

Recruiting

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Spain, France
Novartis Pharmaceuticals

Recruiting

A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy.

Metastatic Castration-resistant Prostate Cancer (mCRPC)

France
Novartis Pharmaceuticals

Recruiting

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

China
British Columbia Cancer Agency

Recruiting

177Lu-HTK03170 in mCRPC With PSMA Positive Disease

Prostate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer

Canada
Crescendo Biologics Ltd.

Recruiting

Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours. (POTENTIA)

Advanced and/or Metastatic Solid Tumours

Spain, United Kingdom, Netherlands, United States
Sichuan University

Enrolling by invitation

Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer

Metastatic Prostate Cancer

China
Novartis Pharmaceuticals

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

China
Canadian Cancer Trials Group
Endocyte; Prostate Cancer Canada

Active, not recruiting

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Prostate Cancer

Canada
Lantheus Medical Imaging
POINT Biopharma

Available

Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Castration-Resistant Prostatic Cancer

United States
Curium US LLC

Completed

Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer

Metastasis From Malignant Tumor of Prostate (Disorder)

United States
Tceleron Therapeutics, Inc.

Terminated

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
Istituto Scientifico Romagnolo per lo Studio e...

Active, not recruiting

Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC) (LU-PSMA)

Metastatic Castration Resistant Prostate Cancer | 68Ga-PSMA PET/CT Positive

Italy
Advanced Accelerator Applications

Terminated

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer (PROter)

Prostatic Neoplasm

United States, Spain
Medical University of Vienna
Lund University; Ziekenhuis Netwerk Antwerpen (ZNA); St. Antonius Hospital; Azienda... and other collaborators

Not yet recruiting

Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study (OLIGOMET)

Prostate Cancer | Prostate Cancer Metastatic | Oligometastasis | Prostate Neoplasm | Oligometastatic Disease | Prostate Cancer Metastatic to Bone
Peking University First Hospital

Not yet recruiting

Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer

Prostate Adenocarcinoma
Novartis Pharmaceuticals

Not yet recruiting

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Metastatic Neuroendocrine Prostate Cancer
The First Affiliated Hospital of Xiamen University

Recruiting

Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer, mCRPC

China
University Hospital, Basel, Switzerland

Not yet recruiting

Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study (PROGNOSTICS)

Castration-resistant Prostate Cancer

Switzerland
Rohan Garje
Janssen Scientific Affairs, LLC

Not yet recruiting

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (LUNAAR)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
University College, London
Novartis; Cancer Research UK; Janssen Pharmaceutica NV

Not yet recruiting

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (STAMPEDE2)

Prostate Cancer Metastatic
Dana-Farber Cancer Institute
Novartis

Recruiting

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Not yet recruiting

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Erasmus Medical Center

Recruiting

Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics (LUTRAC)

Prostate Cancer Metastatic

Netherlands
Peking Union Medical College Hospital

Recruiting

177Lu-LNC1011 in Patients With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

China
Jagiellonian University
University Hospital in Krakow

Recruiting

Clinical Application of the J-PET Scanner Prototype (JPET2Clinic)

Prostatic Neoplasms | Prostatic Hyperplasia | Prostate Cancer | Neuroendocrine Tumors | Neuroendocrine Carcinoma | Prostate Cancer Metastatic

Poland
POINT Biopharma, a wholly owned subsidiary of Eli...
Eli Lilly and Company

Recruiting

[Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer (ACCEL)

Prostate Cancer | Biochemically Recurrent Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer

Canada
Shanghai Changzheng Hospital
Bioray Laboratories

Recruiting

Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC

Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

China
Bayer

Recruiting

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA)

Advanced Metastatic Castration-resistant Prostate Cancer | Prostate Specific Membrane Antigen (PSMA) Expression

Canada, United Kingdom, Belgium
Jonsson Comprehensive Cancer Center

Not yet recruiting

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Prostate Carcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Hospital of Macerata

Not yet recruiting

ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa

Prostate Cancer

Italy
Mayo Clinic

Recruiting

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
University of Washington
Novartis; Institute for Prostate Cancer Research (IPCR)

Not yet recruiting

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Centre Georges Francois Leclerc

Not yet recruiting

Evaluation of the Concordance Between Pre-therapy Dosimetry Performed From 68Ga-PSMA-11 Dynamic PET and Post-treatment Dosimetry of 177Lu-PSMA-617 Vectorized Internal Radiotherapy in Patients With Metastatic Prostate Cancer Resistant to Hormonal Castration. (GaLuPro)

Patients With Metastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
Progenics Pharmaceuticals, Inc.

Not yet recruiting

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Carcinoma

United States
VA Office of Research and Development

Recruiting

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

Prostate Cancer

United States
Dana-Farber Cancer Institute
Blue Earth Diagnostics, Inc

Not yet recruiting

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

Metastatic Prostate Cancer | Advanced Prostate Cancer | Metastatic Prostate Neuroendocrine Carcinoma

United States
Nanjing First Hospital, Nanjing Medical University

Recruiting

Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer

Metastatic Prostate Cancer

China
Novartis Pharmaceuticals

Recruiting

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. (PSMA-DC)

Oligometastatic Prostate Cancer (OMPC)

Japan, Singapore, Canada, Israel, Switzerland, Australia, United States
University of California, San Francisco
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Not yet recruiting

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

Castration-Resistant Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IVB Prostate Cancer AJCC v8

United States
CHU de Quebec-Universite Laval
Canadian Institutes of Health Research (CIHR)

Not yet recruiting

A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy (PRODIGY-1)

Cancer | Prostate Cancer | Metastatic Cancer | Metastatic Prostate Cancer
Istituto Scientifico Romagnolo per lo Studio e...

Recruiting

Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST) (LUST)

Prostate Cancer

Italy
Istituto Scientifico Romagnolo per lo Studio e...

Recruiting

Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours: (LUBASKET)

Cancer

Italy
Novartis Pharmaceuticals

Recruiting

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (PSMACare)

Prostatic Neoplasm

Korea, Republic of, Singapore, United States, Canada, Poland, Spain, Czechia
BAMF Health

Recruiting

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study) (SPECTacular)

Metastatic Castration-resistant Prostate Cancer

United States
University of California, San Francisco
Merck Sharp & Dohme LLC; Prostate Cancer Foundation

Recruiting

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Prostate Cancer | Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

Malignancy

China
Emory University
National Cancer Institute (NCI); Xencor, Inc.

Recruiting

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Castration-Sensitive Prostate Carcinoma

United States
AHS Cancer Control Alberta

Recruiting

A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer

Prostate Cancer | Oncology

Canada

Search clinical trials for: PSMA positive metastatic prostate cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations